Table 3.
Gastric-cancer subgroup (n = 66) | Puncture free survival | Time to next therapeutic puncture | Overall survival |
Catumaxomab group (n = 46) | 44 days | 118 days | 71 days |
Control group (n = 20) | 15 days | 15 days | 44 days |
p value | <0.0001 | <0.0001 | 0.0313 |
Hazard ratio (95% CI) | 0.289 (0.151; 0.554) | 0.143 (0.057; 0.359) | 0.469 (0.232; 0.951) |